Advertisement
Advertisement
aTyr Pharma, Inc. (LIFE)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Follow
At close: 03:59PM EDT
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 1.8800 |
| Open | 1.8600 |
| Bid | 1.8700 x 800 |
| Ask | 1.9000 x 800 |
| Day's Range | 1.8300 - 1.9200 |
| 52 Week Range | 1.8150 - 5.9700 |
| Volume | |
| Avg. Volume | 256,806 |
| Market Cap | 55.698M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Zacks
Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 45.83% and 592.40%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know
Atyr Pharma (LIFE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
